Bond.az White LogoBond.az Black Logo

American Strategic Co. Revenue Drops in Q1 2026

American Strategic Investment Co. revenue drops 40.7% in Q1 2026. Stock at $9.90. Bond.az analysis suggests undervaluation.

Evelyn Lee
ByEvelyn Lee- Senior Editor
|
0

American Strategic Investment Co. (NYSE: NYC) reported a significant revenue decline for Q1 2026. Revenue fell 40.7% year-over-year to $7.3 million, primarily due to the foreclosure of 1140 Avenue of the Americas.

Net loss improved to $7.8 million from $8.6 million a year earlier. The stock recently traded at $9.90, a 20.6% gain over the past week. According to Bond.az analysis, the stock appears undervalued at current levels.

CEO Nicholas Schorsch Jr. stated: 'Our focus remains on reducing recurring expenses and managing the balance sheet.' The company continues strategic reviews of properties like 123 William Street and 196 Orchard Street.

The annual stockholders meeting will be held on June 2, 2026.

More News
Today / 16:03
|
656

Onex Corp Q1 2026: Solid Results

Onex Corporation Q1 2026: Solid results driven by Convex platform and strong capital generation. Stock undervalued according to analysis.

0
Today / 16:02
|
944

RBC Bearings Q4 2026 Earnings Beat Expectations

RBC Bearings reported strong Q4 fiscal 2026 results with EPS and revenue beating expectations, driven by Aerospace & Defense growth.

0
Today / 15:51
|
858

Grupo Mateus Q1 2026: EPS Misses Estimates, Stock Steady

Grupo Mateus Q1 2026 EPS missed by 30.53%, revenue slightly below. Shares stable up 0.47%.

0
Today / 15:33
|
912

TOMI Q1 2026: Revenue growth and 13% stock surge

TOMI Environmental Solutions Q1 2026 revenue rose 5% to $1.65M, stock surged 13%. EPS missed but investor confidence remained high.

0
Today / 15:31
|
482

ARS Pharma Misses Q1 2026 EPS Forecast, Stock Drops

ARS Pharma Q1 2026 EPS miss leads to 8.56% stock drop. Neffy prescriptions triple but high costs pressure profits.

0
Today / 15:10
|
220

Tupy S.A. Q1 2026 loss, revenue beats expectations

Tupy S.A. Q1 2026 results: EPS misses expectations, but revenue beats. Stock declines, but Bond.az analysis shows value potential.

0
Today / 14:40
|
577

Sumitomo Pharma Q4 2025 Beats EPS Forecasts

Sumitomo Pharma Q4 2025 earnings beat EPS forecasts. The company achieved record profitability in FY 2025, driven by strong U.S. sales of ORGOVYX and GEMTESA.

0
Today / 13:51
|
928

MiNK Therapeutics Q1 2026: Strategic Progress

MiNK Therapeutics Q1 2026 earnings: strategic progress, financial results, and updates on AGENT-797 platform.

0
Today / 13:24
|
927

Kepler Weber Q1 2026: Mixed Results

Kepler Weber reported mixed Q1 2026 results with international growth offsetting domestic declines. EBITDA margin stable at 11%.

0
Today / 13:22
|
695

Acumen Pharmaceuticals Beats Q1 2026 EPS Forecast

Acumen Pharmaceuticals beats Q1 2026 EPS forecast with -$0.33, but stock falls on cautious sentiment. Details on ALTITUDE-ad trial and EBD program.

0
Today / 13:21
|
214

Alico Beats Q2 2026 EPS Forecast by 23%

Alico (ALCO) reports Q2 fiscal 2026 EPS of $1.49, beating estimates by 23%. The company pivots from citrus to land monetization, boosting profitability.

0
Today / 13:20
|
536

PAVmed Q1 2026: Restructuring Gains Highlighted

PAVmed Inc. reported Q1 2026 results with restructuring gains and product development progress. Stock up 3.1%.

0
...
American Strategic Co. Revenue Drops in Q1 2026 | Bond.az